Megestrol attenuates the hormonal response to CCK-4-induced panic attacks

Depression and Anxiety

Volumn 23, Issue 3, 2006, Pages 139-144

  Raedler, Thomas J ^a   Jahn, Holger ^a   Goedeken, Birgit ^a   Gescher, Dorothee M ^a   Kellner, Michael ^a   Wiedemann, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

ACTH; CCK4; Cortisol; Megestrol; Panic disorder

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE; MEGESTROL ACETATE; PLACEBO; TETRAGASTRIN;

ACUTE PANIC INVENTORY; ADULT; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; CORTICOTROPIN RELEASE; HORMONE RELEASE; HUMAN; HYDROCORTISONE RELEASE; IMMUNORADIOMETRIC ASSAY; INTERNATIONAL DIAGNOSTIC CHECKLIST; MALE; MENTAL DISEASE; NORMAL HUMAN; PANIC; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RATING SCALE; SEX DIFFERENCE; STRESS; VISUAL ANALOG SCALE;

ADRENOCORTICOTROPIC HORMONE; ADULT; AROUSAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MEGESTROL; PANIC; PITUITARY-ADRENAL SYSTEM; PREMEDICATION; TETRAGASTRIN;

EID: 33646596345     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20147     Document Type: Article

References (39)

1. Altshuler LL, Hendrick V, Cohen LS. 1998. Course of mood and anxiety disorders during pregnancy and the postpartum period. J Clin Psychiatry 59(Suppl 2):29-33.
2. Bitran D, Hilvers RJ, Kellogg CK. 1991. Anxiolytic effects of 3 alpha-hydroxy-5 alpha[beta]-pregnan-20-one: Endogenous metabolites of progesterone that are active at the GABAA receptor. Brain Res 561:157-161.
3. Bitran D, Shiekh M, McLeod M. 1995. Anxiolytic effect of progesterone is mediated by the neurosteroid allopregnanolone at brain GABAA receptors. J Neuroendocrinol 7:171-177.
4. Bradwejn J, Koszycki D. 2001. Cholecystokinin and panic disorder: Past and future clinical research strategies. Scand J Clin Lab Invest Suppl 234:19-27.
5. Bradwejn J, Koszycki D, Shriqui C. 1991. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder: Clinical and behavioral findings. Arch Gen Psychiatry 48:603-610.
6. Cohen LS, Sichel DA, Dimmock JA, Rosenbaum JF. 1994a. Impact of pregnancy on panic disorder: A case series. J Clin Psychiatry 55:284-288.
7. Cohen LS, Sichel DA, Dimmock JA, Rosenbaum JF. 1994b. Postpartum course in women with preexisting panic disorder. J Clin Psychiatry 55:289-292.
8. Cook BL, Noyes R Jr, Garvey MJ, Beach V, Sobotka J, Chaudhry D. 1990. Anxiety and the menstrual cycle in panic disorder. J Affect Disord 19:221-226.
9. de Montigny C. 1989. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers: Preliminary findings. Arch Gen Psychiatry 46:511-517.
10. Dillon DJ, Gorman JM, Liebowitz MR, Fyer A, Klein DF. 1987. Measurement of lactate-induced panic and anxiety. Psychiatry Res 20:97-105.
11. Gorman JM, Kent JM, Sullivan GM, Coplan JD. 2000. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 157: 493-505.
12. Gulinello M, Gong QH, Li X, Smith SS. 2001. Short-term exposure to a neuroactive steroid increases alpha4 GABA(A) receptor subunit levels in association with increased anxiety in the female rat. Brain Res 910:55-66.
13. Gulinello M, Smith SS. 2003. Anxiogenic effects of neurosteroid exposure: Sex differences and altered GABAA receptor pharmacology in adult rats. J Pharmacol Exp Ther 305:541-548.
14. Hertzberg T, Wahlbeck K. 1999. The impact of pregnancy and puerperium on panic disorder: A review. J Psychosom Obstet Gynaecol 20:59-64.
15. Hettema JM, Neale MC, Kendler KS. 2001. A review and metaanalysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry 158:1568-1578.
16. Hiller W, von Bose M, Dichtl G, Agerer D. 1990. Reliability of checklist-guided diagnoses for DSM-III-R affective and anxiety disorders. J Affect Disord 20:235-247.
17. Kaspi SP, Otto MW, Pollack MH, Eppinger S, Rosenbaum JF. 1994. Premenstrual exacerbation of symptoms in women with panic disorder. J Anxiety Disord 8:131-138.
18. Kellner M, Yassouridis A, Hua Y, Wendrich M, Jahn H, Wiedemann K. 2002. Intravenous C-type natriuretic peptide augments behavioral and endocrine effects of cholecystokinin tetrapeptide in healthy men. J Psychiatr Res 36:1-6.
19. Klein DF. 1993. False suffocation alarms, spontaneous panics, and related conditions: An integrative hypothesis. Arch Gen Psychiatry 50:306-317.
20. Kontula K, Paavonen T, Luukkainen T, Andersson LC. 1983. Binding of progestins to the glucocorticoid receptor: Correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes. Biochem Pharmacol 32: 1511-1518.
21. Koszycki D, Zacharko RM, Le Melledo JM, Bradwejn J. 1998. Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: A comparison of panickers and nonpanickers. Depress Anxiety 8:1-7.
22. Lambert JJ, Belelli D, Hill-Venning C, Peters JA. 1995. Neurosteroids and GABAA receptor function. Trends Pharmacol Sci 16: 295-303.
23. Le Melledo JM, Jhangri GS, Lott P, Tait GR, McManus K, Geddes M, Chrapko W, Lara N. 2001. Effect of medroxyprogesterone pretreatment on pentagastrin-induced panic symptoms in females with panic disorder. Psychiatry Res 101:237-242.
24. Le Melledo JM, Merani S, Koszycki D, Bellavance F, Palmour R, Gutkowska J, Steinberg S, Eichet DG, Bradwejn J. 1999. Sensitivity to CCK-4 in women with and without premenstrual dysphoric disorder (PMDD) during their follicular and luteal phases. Neuropsychopharmacology 20:81-91.
25. Northcott CJ, Stein MB. 1994. Panic disorder in pregnancy. J Clin Psychiatry 55:539-542.
26. Pigott TA. 1999. Gender differences in the epidemiology and treatment of anxiety disorders. J Clin Psychiatry 60(Suppl 18): 4-15.
27. Rupprecht R. 2003. Neuroactive steroids: Mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology 28:139-168.
28. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22-33.
29. Sheikh JI, Leskin GA, Klein DF. 2002. Gender differences in panic disorder: Findings from the National Comorbidity Survey. Am J Psychiatry 159:55-58.
30. Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J. 1997. Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci 22:332-340.
31. Siminoski K, Goss P, Drucker DJ. 1989. The Cushing syndrome induced by medroxyprogesterone acetate. Ann Intern Med 111: 758-760.
32. Villeponteaux VA, Lydiard RB, Laraia MT, Stuart GW, Ballenger JC. 1992. The effects of pregnancy on preexisting panic disorder. J Clin Psychiatry 53:201-203.
33. Wank SA, Pisegna JR, de Weerth A. 1992. Brain and gastrointestinal cholecystokinin receptor family: Structure and functional expression. Proc Natl Acad Sci USA 89:8691-8695.
34. Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, Joyce PR, Karam EG, Lee CK, Lellouch J, Lepine JP, Newman SC, Oakley-Browne MA, Rubio-Stipec M, Wells JE, Wickramaratne PJ, Wittchen HU, Yeh EK. 1997. The cross-national epidemiology of panic disorder. Arch Gen Psychiatry 54: 305-309.
35. Wiedemann K, Hirschmann M, Knaudt K, Rupprecht R, Seier FE, Holsboer F. 1998. Sleep endocrine effects of megestrol acetate in healthy men. J Neuroendocrinol 10:719-727.
36. Wiedemann K, Jahn H, Yassouridis A, Kellner M. 2001. Anxiolytic-like effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: Preliminary findings. Arch Gen Psychiatry 58:371-377.
37. Wiedemann K, Lauer CJ, Hirschmann M, Knaudt K, Holsboer F. 1997. Sleep-endocrine effects of mifepristone and megestrol acetate in healthy men. Am J Physiol 274:E139-E145.
38. Yonkers KA. 1997. Anxiety symptoms and anxiety disorders: How are they related to premenstrual disorders? J Clin Psychiatry 58(Suppl 3):62-67.
39. Zwanzger P, Baghai TC, Schuele C, Strohle A, Padberg F, Kathmann N, Schwarz M, Moller HJ, Rupprecht R. 2001. Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. Neuropsychopharmacology 25:699-703.